7TM Pharma successfully conducts clinical Phase I trial of its first in class peripheral CB1 receptor antagonist TM38837 demonstrating restriction from the human CNS

Press Release Thursday, November 11, 2010

7TM Pharma completes positron emission tomography preclinical research program to successfully demonstrate peripheral restriction of its CB1 receptor antagonist TM38837

Press Release Monday, July 12, 2010

7TM Pharma receives milestone payment from asthma and allergy collaboration

Press Release Wednesday, May 26, 2010

A potential new treatment for cancer supportive care and gastrointestinal diseases

Press Release Thursday, April 22, 2010

7TM Pharma successfully conducts clinical phase I trial with its second generation CB1 receptor antagonist

Press Release Thursday, February 04, 2010